Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis

Schizophrenia Bulletin
Jian-Ping ZhangTodd Lencz

Abstract

Findings from the Psychiatric Genomics Consortium genome-wide association study (GWAS) showed that variation at the DRD2 locus is associated with schizophrenia risk. However, the functional significance of rs2514218, the top DRD2 single nucleotide polymorphism in the GWAS, is unknown. Dopamine D2 receptor binding is a common mechanism of action for all antipsychotic drugs, and DRD2 variants were related to antipsychotic response in previous studies. The present study examined whether rs2514218 genotype could predict antipsychotic response, including efficacy and adverse events, in a cohort of patients with first episode of psychosis treated with either risperidone or aripiprazole for 12 weeks. Subjects were genotyped using the Illumina Infinium HumanOmniExpressExome array platform. After standard quality control, data from 100 subjects (49 randomly assigned to treatment with aripiprazole and 51 assigned to risperidone) was available for analysis. Subjects were assessed for psychotic symptomatology and medication-related adverse events weekly for 4 weeks, then biweekly for 8 weeks. Linear mixed model analysis revealed that the homozygotes for the risk (C) allele at rs2514218 had significantly greater reduction in positive sympto...Continue Reading

References

Nov 1, 1991·The American Journal of Psychiatry·K L DavisM Davidson
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Feb 9, 2000·Psychopharmacology·G Remington, S Kapur
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David A ShapiroRichard Mailman
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shitij Kapur, David Mamo
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Mar 3, 2010·The American Journal of Psychiatry·Jian-Ping ZhangAnil K Malhotra
Jul 29, 2010·Pharmacogenetics and Genomics·Todd LenczAnil K Malhotra
Aug 18, 2010·The Pharmacogenomics Journal·D J MüllerJ L Kennedy
Oct 7, 2010·The Journal of Clinical Psychiatry·John M Kane, Christoph U Correll
Dec 18, 2010·Expert Opinion on Drug Metabolism & Toxicology·Jian-Ping Zhang, Anil K Malhotra
Nov 16, 2011·Molecular Psychiatry·A K MalhotraT Lencz
Apr 25, 2012·Frontiers in Psychology·Arielle S SelyaRobin J Mermelstein
Jul 6, 2014·The British Journal of Psychiatry : the Journal of Mental Science·Oliver D Howes, Shitij Kapur
Jul 25, 2014·Nature·UNKNOWN Schizophrenia Working Group of the Psychiatric Genomics Consortium
Apr 15, 2015·Molecular Psychiatry·T Lencz, A K Malhotra
Sep 27, 2015·Schizophrenia Bulletin·Joey W TrampushAnil K Malhotra

❮ Previous
Next ❯

Citations

Feb 13, 2016·Trends in Molecular Medicine·Shira Modai, Noam Shomron
Aug 16, 2016·Clinics in Laboratory Medicine·Rif S El-MallakhKristen K Reynolds
Apr 4, 2017·ACS Chemical Neuroscience·Austen B Casey, Clinton E Canal
Mar 13, 2018·Current Opinion in Psychiatry·Clement C ZaiJames L Kennedy
Jul 12, 2017·Biological Research for Nursing·Rose Mary Xavier, Allison Vorderstrasse
Nov 7, 2018·The Mental Health Clinician·Melanie RouthieauxErika E Tillery
Sep 13, 2018·The Mental Health Clinician·Tonya Gross, Jeremy Daniel
Mar 29, 2018·Current Psychiatry Reports·Jian-Ping Zhang, Anil K Malhotra
Feb 6, 2020·Focus : Journal of Life Long Learning in Psychiatry·Shani SternFred H Gage
Nov 16, 2016·Pharmacogenetics and Genomics·Qingqin LiNicholas J Schork
May 26, 2018·Open Biology·Shani SternFred H Gage
May 6, 2019·Journal of Molecular Neuroscience : MN·Margarita V AlfimovaVera E Golimbet
Dec 28, 2019·Pharmaceutics·Stefano FortinguerraAlessandro Buriani
Apr 22, 2020·NPJ Schizophrenia·Carina Seah, Kristen J Brennand
Feb 12, 2017·Schizophrenia Bulletin·Theresa WimberleyHenriette Thisted Horsdal
Jan 29, 2019·Frontiers in Psychiatry·Antonio RampinoJean Martin Beaulieu
Dec 15, 2020·Behavioural Brain Research·Maria J ArranzMarta H Hernández
May 29, 2021·Schizophrenia Research·Amanda J LisowayJames L Kennedy
Apr 20, 2021·European Psychiatry : the Journal of the Association of European Psychiatrists·Antonio RampinoGiuseppe Blasi
Jun 16, 2021·Clinical Pharmacology and Therapeutics·Farhana IslamDaniel J Müller
Sep 16, 2021·Child Psychiatry and Human Development·Margarita V AlfimovaVera E Golimbet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here